Daiichi Sankyo Co Ltd (Daiichi Sankyo) develops, manufactures and markets drugs to address unmet medical needs in various diseases and disorders. The company operates through one segments: Pharmaceutical Operation. It generates revenue from three product categories; Prescription drugs, Healthcare (OTC) products, and Others. The company offers Pralia, a treatment for osteoporosis; Tenelia, a treatment for type II diabetes mellitus; Ranmark, a treatment for bone complications caused by bone metastases from tumors; Lixiana, an anticoagulant; Olmetec, an antihypertensive agent; Rezaltas, an antihypertensive agent; and Enhertu, antitumor agent.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Daiichi Sankyo develops innovative new products to address some of the major unmet medical needs of patients suffering from various types of cancers. It spent JPY341,570.0 million on its R&D in FY2023, which as a percentage of revenue, stood at 26.7%. Its R&D focuses on three areas: Oncology, Specialty Medicines and Cell Therapy. The pipeline encompasses antibody drug conjugate (ADC) and Alpha franchise. Some of the late stage pipeline products under ADC are DESTINY-Breast05, DESTINY-Breast06, DESTINY-Breast09, DESTINY-Breast11, TROPION-Lung01, TROPION-Lung07, TROPION-Lung08, TROPION-Breast01, TROPION-Breast02, TROPION-Breast03 and HERTHENA-Lung02 in Phase III trial for the treatment of different types of cancers. Major pipeline products under Alpha are Pexidartinib for tenosynovial giant cell tumor; Esaxerenone for diabetic nephropathy; DS-5670 for Covid-19 and VN-0102/JVC-001 vaccine for Measles infection.